Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Aldosterone dysregulation contributes to hypertension. Lorundrostat, an aldosterone synthase inhibitor, was evaluated in a multicenter, double blind, randomized, placebo controlled trial involving participants with uncontrolled hypertension despite receiving two to five antihypertensive medications. The primary endpoint was the change in 24 hour average systolic blood pressure from baseline to week 12. Results showed that lorundrostat at 50 mg daily led to a placebo adjusted reduction of 7.9 mm Hg in systolic blood pressure, with a dose-adjustment strategy yielding a 6.5 mm Hg reduction. Hyperkalemia occurred in 5-7% of participants receiving lorundrostat. The study concluded that lorundrostat effectively lowers blood pressure in patients with uncontrolled hypertension, with a safety profile consistent with aldosterone-targeting therapies.

Aldosterone dysregulation contributes to hypertension. Lorundrostat, an aldosterone synthase inhibitor, was evaluated in a multicenter, double blind, randomized, placebo controlled trial involving participants with uncontrolled hypertension despite receiving two to five antihypertensive medications. The primary endpoint was the change in 24 hour average systolic blood pressure from baseline to week 12. Results showed that lorundrostat at 50 mg daily led to a placebo adjusted reduction of 7.9 mm Hg in systolic blood pressure, with a dose-adjustment strategy yielding a 6.5 mm Hg reduction. Hyperkalemia occurred in 5-7% of participants receiving lorundrostat. The study concluded that lorundrostat effectively lowers blood pressure in patients with uncontrolled hypertension, with a safety profile consistent with aldosterone-targeting therapies.